Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 24, 2019, reports on Jaguar Health, Inc.'s first quarter 2019 results. The Company is an emerging growth company focused on the commercialization and development of Mytesi (crofelemer), its first-in-class, FDA-approved anti-secretory human prescription drug.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1.
Material Changes
The filing does not detail specific material changes versus prior periods within the text body. It references the attached press release for information regarding current and planned commercial, educational, and product development activities.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are contained within the press release furnished as Exhibit 99.1. The filing itself does not elaborate on these items beyond referencing the existence of the report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2019 financial results including revenue and net loss.
- Verify cash position and burn rate details not included in this summary text.
- Examine the press release for updates on Mytesi commercialization and product development milestones.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.